RecruitingNCT06148298

Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer

Cell-free Chromatin Immunoprecipitation (CfChIP) from Blood Plasma As a Diagnostic and Prognostic Tool in Pancreatic Ductal Adenocarcinoma

Sponsor

University of Central Florida

Enrollment

24 participants

Start Date

May 24, 2023

Study Type

OBSERVATIONAL

Conditions

Cancer of Pancreas

Summary

The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study develops and validates a new blood-based cancer detection method called cell-free DNA chromatin immunoprecipitation (cfChIP), which analyzes DNA fragments floating in the bloodstream to look for signals associated with cancer. The goal is to enable earlier and less invasive cancer diagnosis compared to traditional biopsies. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with pancreatic cancer - You are able to understand and sign an informed consent form **You may NOT be eligible if...** - You are under 18 years old - You are unable to provide informed consent (for example, due to cognitive impairment or legal status) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.